1. Home
  2. AITR vs BCAB Comparison

AITR vs BCAB Comparison

Compare AITR & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AITR
  • BCAB
  • Stock Information
  • Founded
  • AITR 2022
  • BCAB 2007
  • Country
  • AITR United States
  • BCAB United States
  • Employees
  • AITR N/A
  • BCAB N/A
  • Industry
  • AITR
  • BCAB Medicinal Chemicals and Botanical Products
  • Sector
  • AITR
  • BCAB Health Care
  • Exchange
  • AITR Nasdaq
  • BCAB Nasdaq
  • Market Cap
  • AITR 82.6M
  • BCAB 96.2M
  • IPO Year
  • AITR 2023
  • BCAB 2020
  • Fundamental
  • Price
  • AITR $10.54
  • BCAB $2.08
  • Analyst Decision
  • AITR
  • BCAB Strong Buy
  • Analyst Count
  • AITR 0
  • BCAB 2
  • Target Price
  • AITR N/A
  • BCAB $6.00
  • AVG Volume (30 Days)
  • AITR 71.3K
  • BCAB 1.6M
  • Earning Date
  • AITR 01-01-0001
  • BCAB 11-08-2024
  • Dividend Yield
  • AITR N/A
  • BCAB N/A
  • EPS Growth
  • AITR N/A
  • BCAB N/A
  • EPS
  • AITR N/A
  • BCAB N/A
  • Revenue
  • AITR N/A
  • BCAB N/A
  • Revenue This Year
  • AITR N/A
  • BCAB N/A
  • Revenue Next Year
  • AITR N/A
  • BCAB N/A
  • P/E Ratio
  • AITR N/A
  • BCAB N/A
  • Revenue Growth
  • AITR N/A
  • BCAB N/A
  • 52 Week Low
  • AITR $10.11
  • BCAB $1.14
  • 52 Week High
  • AITR $10.57
  • BCAB $4.02
  • Technical
  • Relative Strength Index (RSI)
  • AITR 78.43
  • BCAB 55.80
  • Support Level
  • AITR $10.51
  • BCAB $1.87
  • Resistance Level
  • AITR $10.57
  • BCAB $2.13
  • Average True Range (ATR)
  • AITR 0.01
  • BCAB 0.12
  • MACD
  • AITR -0.00
  • BCAB 0.00
  • Stochastic Oscillator
  • AITR 83.33
  • BCAB 68.90

About AITR AI TRANSPORTATION ACQUISITION CORP Ordinary shares

AI Transportation Acquisition Corp is a blank check company.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Share on Social Networks: